Antimicrobial compositions and methods of using them

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to antimicrobial compositions and methods for using them, and aims at the preoperative skin processing and disinfection, wound care, and as a disinfectant for sterilisation of surgical instruments. An antimicrobial composition contains at least approximately 30 wt % or more of C1-C6 alcohol, approximately 1.5 wt % to 15 wt % of citric acid, approximately 0.01 wt % to 1 wt % of paraben, and approximately 0.01 wt % to 0.2 wt % of a redox compound. The antimicrobial composition has pH from approximately 3 to approximately 7. The other aspects present an applicator that comprises an absorbent material and an absorbed antimicrobial composition, or an adsorbent material and a handle comprising an amount of the antimicrobial composition.

EFFECT: using the group of inventions provides effective and fast elimination of microorganisms particularly found on the skin surface, thereby providing the antimicrobial effect stable for a long period of time after use.

33 cl, 12 dwg, 2 tbl, 6 ex

 

The present invention relates to antimicrobial compositions suitable for use as a means for pre-processing and other purposes disinfection of the skin, for use in wound care and as a disinfectant for sterilization of surgical instruments. In particular, the application relates to antimicrobial agents that are effective to achieve rapid destruction of microorganisms present on the skin surface, which exhibit antimicrobial effect, which is sustainable over a long period of time after application.

In the prior art is often desirable to remove or reduce the presence of microorganisms to prevent infection and the spread of microorganisms. As an example, in order to reduce the frequency of postoperative infections in patients in place of surgical intervention or injection catheter before surgery or before the introduction of needle or catheter surrounding skin is treated to eliminate or reduce the presence of microorganisms that can cause infection. In addition, the medical staff involved in the surgical procedure, must be properly disinfected. In the case of medical staff standard surgeon is ical procedures require the disinfection of the surface of the skin of the surgeon and operating staff before surgery. Effective preoperative skin cleansing is critical to reduce the risk of infection to the patient.

Another means of reducing the frequency of infection in the surgical site during the surgical procedure is to ensure that surgical instruments used in surgery, was not infected. This can be achieved, for example, by immersing surgical instruments in a container of disinfectant fluid to contact the patient's tissue during surgery. Alternatively, if the tool should be used during the operation several times, such a tool can be immersed in a container of disinfectant fluid between applications.

In addition to the preparation for surgery is often necessary to disinfect or be subjected to sanitary treatment the skin surrounding the outer wound or ulcer man. In addition to the antimicrobial effect of disinfectant products for cleaning wounds or sores should also be designed so as not to injure the damaged tissue wounds or sores.

Formulations of drugs used for disinfection of skin, wounds, ulcers and surgical instruments, preferably should contain antimicrobial compositions that are fast. An example of a fast-acting composition is a lower alcohol, such as,for example, ethanol or isopropyl alcohol. Moreover, particularly in relation to compositions used for disinfection of surfaces of the skin, wounds and ulcers, such compositions preferably should exhibit stability over a long period of time. Lower alcohols evaporate rapidly and do not have sufficient antimicrobial effect on the skin surface for the manifestation of a high degree of stability. For this and other reasons, lower alcohols as such are not particularly effective for use as a means for pre-processing or other applications that require a higher level of resistance.

The United States Food and Drug Administration (FDA) has developed the functional requirements for the new antiseptic compositions proposed for use as a preoperative detergent or surgical detergent for hand. Such functional requirements require that the composition for use as a means for pre-processing or surgical means for processing the hands had a wide range, fast action and resistance. The term "broad spectrum" is defined in such circumstances, as having antimicrobial activity against many gram-positive and gram-negative bacteria and yeast. In 1994 the FDA has established research methods, with the aid of the condominiums which are testing new antiseptics. Requirements for drugs for the treatment of the skin of patients before the operation specified in the FDA Tentative Final Monograph for Healthcare Antiseptic Drug Products (Federal Register 59 [116], Jun. 17, 1994: pp.31402-31452). Methods in vivo studies described in the FDA Tentative Final Monograph in the present description, hereinafter referred to as test "1994 FDA TFM.

Antimicrobial effectiveness of drugs for preoperative treatment of hands and exposed skin surgery, can also be investigated by any appropriate known test to demonstrate adequate disinfection of the resident flora of the skin. Examples of such tests are ASTM E 1115-02, “Standard test method for evaluation of surgical hand scrub formulations” (ASTM International) and EN 12791:2005, “Chemical disinfectants and antiseptics, Surgical hand disinfection, Test method and requirement (phase 2, step 2),” (CEN-Comitee Europeen de normalization, Brussels, Belgium). ASTM E 1173-01 provides "Standard test method for evaluation of preoperativem precatheterization, or perinjection skin preparations".

A product for research in accordance with the dough 1994 FDA TFM applied to the prepared place of treatment of the skin in the abdomen and groin area patients by lubricating the skin composition, then place skin treatment to give dry coating and drying in the present description are called together as "processing"). Reduce resident flora of the skin is measured at predetermined time intervals after treatment. In particular, measuring the amount of bacteria on the spot treatment skin floor is up prior to application of the product to assess the "source" of the number of bacteria, 10 minutes after the treatment to assess the "initial" level of destruction and 6 hours after treatment to assess sustainability. Test 1994 FDA TFM requires that the composition has reduced the average number of bacteria on 2 log10(also referred to in this description as "2 log destruction") on the skin of the abdomen for 10 minutes after treatment, compared with the original number, and the average number of bacterial cells in the treatment site should not subsequently exceed original for 6 hours. In addition, the composition should reduce the average number of bacteria on 3 log10(also referred to in this description as "3 log destruction") on the skin in the groin within 10 minutes after treatment, compared with the original number in this place, and the average number of bacterial cells in the treatment site should not subsequently exceed the original within 6 hours after processing.

Whereas for the compliance test, the 1994 FDA TFM can be used different approaches, one problem that occurs is the development of a product with sufficient antibacterial properties, which is also well tolerated in contact with human skin. For example, while really good results source of destruction and sustainability can be achieved using strong is acidic compositions alcohol-based (i.e. having a pH less than 3), such as, for example, a composition containing a high concentration of the lower alcohol and the acid, low pH levels can have a harmful effect on the skin of the patient or medical personnel. In addition, the low pH level does not allow the inclusion of additional antimicrobial ingredients that can enhance the antimicrobial function of composition, as many antimicrobial compounds are inactivated such strongly acidic composition. In other approaches the use of a rigid oxidative halogen, such as chlorine or iodine, to achieve a suitable stability; however, these oxidative halogen poorly tolerated by many patients and medical staff. For example, a significant number of people are allergic to iodine.

Moreover, while it was found that the products developed in the United States for several years after the introduction of the test 1994 FDA TFM, satisfy the test of the 1994 FDA TFM and approved for sale as a means for pre-processing or other products for skin disinfection, the FDA in 2005 were proposed more stringent requirements for such products for skin treatment (hereinafter in the present description "the requirements of the 2005 FDA"). According to the FDA 2005 not only the average Log reduction of microorganisms on the treated skin surface must in order to comply with the parameters of the 1994 FDA TFM at predetermined points in time after each treatment, but, in addition, the requirements of the FDA 2005 indicate that the lower boundary of the 95% confidence interval Log reduction in the number of bacteria also exceeded the performance criteria specified in the 1994 FDA TFM (i.e. criteria for the level of microorganisms within 10 minutes after treatment and 6 hours after treatment, compared with the original quantities in the abdomen and groin).

Although the authors know of no publicly available data regarding whether any products for skin disinfection, currently available in the U.S. market, the FDA 2005 or not, in the relevant field of technology is speculation that only few or perhaps none of the products currently available in the U.S. market, do not meet the requirements of FDA 2005. Like it or not, there is a need for additional work in this area of technology. In particular, the antimicrobial composition, which is well tolerated in contact with human skin, which is fast and shows good stability over a long period of time. The present invention solves this need.

The invention

The present invention relates to antimicrobial compositions for use as a preoperative facilities for treatment of skin and other CE is her skin disinfection. In particular, but not exclusively, the invention relates to antimicrobial compositions, which is well tolerated on the skin, which is fast and resistant over a long period of time. The invention also provides an antimicrobial composition that can be applied for a very short period of time without stifling its excellent fast-acting antimicrobial effect and its stability. Antimicrobial compositions described in the present description, are also effective for use in wash and disinfect open wounds and ulcers, and for use in the disinfection of surgical instruments and other surfaces.

In one embodiment of the present invention provided an alcohol-based antimicrobial composition that contains an organic acid; paraben and redox connection. In one embodiment, the antimicrobial composition has a pH from about 3 to about 7. In another embodiment, the antimicrobial composition comprises an alcohol, organic acid, paraben, redox compound and an organic salt. In yet another embodiment, provided an antimicrobial composition that includes alcohol1-C6at a concentration of at least AP is sustained fashion 30 percent by weight; citric acid in a concentration of from about 4 percent to about 8 percent by weight; paraben at a concentration of up to about 0.6 percent by weight; and methylene blue at a concentration of up to about 0.2 percent by weight. In another embodiment, the antimicrobial composition has a pH from about 3 to about 7. In yet another embodiment, the composition also contains citrate salt, dissolved or dispergirovannoyj it.

In another embodiment, the present invention provides a method of producing antimicrobial composition that includes (1) obtaining a solution of alcohol With1-C6at a concentration of at least about 30 percent by weight; (2) dissolution in organic acid, parabens, and redox compounds to provide antimicrobial compositions exhibiting rapid antimicrobial effect and residual efficacy on the skin surface. In another embodiment, the method includes dissolving the organic acid in solution. In another embodiment, the method involves dissolution of the pH regulator in the solution to provide a solution having a pH from about 3 to about 8.

In another aspect of the invention provides a method that includes (1) providing alcohol, antimi the detailed composition, containing organic acid in a concentration of from about 1.5 percent to about 15 percent by weight calculated on the total weight of the composition; paraben and redox compound; where the composition has a pH from about 3 to about 7; (2) identification of the patient with a local presence of microorganisms; and (3) applying an effective amount of the composition to the skin surface of the patient to reduce the presence of microorganisms. In one embodiment, the composition is applied by applicator comprising an absorbent material absorbed therein an antimicrobial composition; and processing the surface of the skin antimicrobial composition within about sixty seconds. In another embodiment, the composition is applied by treating the surface of the skin antimicrobial composition for approximately thirty seconds. As used in the present description, the term "processing" is intended to include various means of applying the antimicrobial composition to the skin surface of the patient, including, for example, wiping, washing, being covered, application by spraying and mopping and such.

In another one embodiment, the present invention provides a kit for treatment of the surface of the skin, including antimicrobial to the position, as described in the present description, and at least one applicator for applying the composition.

In another one embodiment, the invention provides an applicator that is created for the application of the antimicrobial composition, as described in the present description, the surface of the skin. The applicator includes an absorbent material and absorbed it antimicrobial composition.

Additional embodiments of variants of the invention, characteristics, aspects, advantages, objectives and benefits of the present invention will be apparent from the detailed description presented below.

Brief description of drawings

Figure 1 presents a schematic illustration of a variant of the applicator for applying the antimicrobial composition.

Figure 2 presents a top view of one particular variant of the applicator illustrated in figure 1.

Figure 3 presents the cross-side view of an alternative applicator for applying the antimicrobial composition.

4 shows a top view of another alternative applicator for applying the antimicrobial composition.

Figure 5 presents a perspective representation of another alternative applicator for applying the antimicrobial composition.

Figure 6 presents a side view of another alternate version of the SW control the ora for applying the antimicrobial composition.

Figure 7 presents a schematic illustration of a variant set for disinfection.

On Fig presents a schematic illustration of an alternative set for disinfection.

Figure 9 presents a graph depicting the results of the test to reduce the number of bacteria in the groin area, described in example 5.

Figure 10 presents a graph depicting the results of the test to reduce the number of bacteria in the stomach that is described in example 5.

Figure 11 presents a graph depicting the reduction of bacteria compared with the time of application in the groin area, determined as described in example 6.

On Fig presents a graph depicting the reduction of bacteria compared with the time of deposition in the abdominal area, as defined, as described in example 6.

Detailed description of representative embodiments of the invention

While the present invention may take many different alternatives, for the purpose of providing understanding of the principles of the invention will be further made reference to representative embodiments of the invention and description of this will be used specific language. However, it should be understood that in this way not be construed to limit the scope of the invention. Any changes or additional mod is the codification of the described embodiments of the invention and any additional applications of the principles described in the present description, are provided as is quite obvious to the person skilled in the art to which the invention relates.

The present invention provides compositions, methods, devices and kits that are useful for antimicrobial therapy. In one of the embodiments provided an antimicrobial composition which is effective when used for disinfection or sanitary processing region of human skin. As used in the present description, the term "antimicrobial composition" refers to a composition that is effective to reduce or eliminate the presence of microorganisms, including one or more of bacteria, viruses, fungi or spores. In one of the embodiments of the antimicrobial compositions in accordance with the present invention offers certain advantages while ensuring rapid bactericidal properties in combination with the resistance after application of the composition. As used in this description the words "rapid bactericidal properties" is intended to refer to the ability of the composition to achieve at least a 3 Log kill bacteria on the lower boundary of the 95% confidence interval on the surface of the skin of the groin during a period of 10 minutes after treatment (i.e. coating composition and drying the skin surface), relative to which icesta bacterial colony forming units (CFU (CFU)), present on the surface prior to application of the composition (i.e. the "source"), and at least 2 Log destruction of bacteria at the lower boundary of the 95% confidence interval on the surface of the skin of the abdomen relative to the source during a period of 10 minutes after spraying. The threshold of 10 minutes is consistent with the requirements of the FDA for a product in pre-processing. The term "stability" refers to the ability of the composition, which shows the original bactericidal properties, to prevent re-colonization of skin surface bacteria to such an extent that the number of bacteria reached the original level after six hours after processing.

Requirements test 1994 FDA TFM and requirements of the 2005 FDA to sustainability are moderate. As will be obvious to the person skilled in the art, at any time during which the antimicrobial composition, quickly destroy a high percentage of microorganisms on the skin surface, deposited on the surface of the skin, for any microorganisms remaining on the skin or present on adjacent surfaces of the skin, it takes time for the recolonization of the treated area of skin to a level close to the original. Moreover, the more pronounced the original destruction is achieved antimicrobial compositions, the more time it will take for bacteria to popcorn the first settlement of the treated area of the skin to the level before treatment.

To study the rate and magnitude of the initial destruction and sustainability destruction using a dough 1994 FDA TFM, determined the initial number of colony forming units of microorganisms per square centimeter of the selected area of the treated skin (CFU/cm2). The results were obtained by determining the number of CFU/cm2on the treated surface of the skin at a selected time after the treatment the skin surface of the test composition. To meet the requirements of the 1994 FDA TFM tools for pre-processing, used the skin surface is in the groin (inguinal) and in the abdomen, and the 1994 FDA TFM requires a means for pre-processing showed an average of 3 Log destruction in the groin area after 10 minutes after spraying the surface of the skin, secondary 2 Log destruction in the abdomen after 10 minutes after treatment, and that the microorganisms did not return to the initial level on any test surface after 6 hours after treatment. For more stringent requirements of the 2005 FDA for approval of a new test composition by the FDA for use as a means for pre-processing, the lower bound 95% confidence interval for mean log reduction for the tested product must be at least 2 log in the abdomen and 3 log itogovoi area 10 minutes after the moment of treatment and thereafter not to exceed the original six (6) hours. As will be obvious to the person skilled in the art to meet this standard, the test product should be much higher than the average 2 Log destruction or 3 Log destruction, respectively, at time 10 minutes after the treatment (i.e. to possess a very effective source of destruction). In addition, the product exhibiting a more complete destruction after 10 minutes after treatment, should have great potential to prevent recolonization of the skin surface within 6 hours after treatment relative to the product with less effective destruction 10 minutes after processing.

It was found that the compositions described in the present description, show a surprisingly fast and strong source of antimicrobial effect and unexpectedly strong resistance. Moreover, the compositions described in the present description, consist of ingredients that have no known adverse effects on human skin, including, for example, no known allergic reactions or irritations. With reference to one representative version of the implementation of the compositions described in the examples below (referred to in this description as a "test composition"), it was shown that the tested composition exhibits more than 3 Log destruction in the area of abdominal skin after 10 minutes or more is than the average 4 Log destruction in the groin area after 10 minutes after treatment compared with baseline levels, SOME directly before application of the test composition. Even more surprising was the fact that the test composition has surpassed the requirements for the 10-minute destruction made by the FDA in 2005 immediately after treatment, when the test composition was applied onto the surface of the skin after treatment, at which application of the product was performed by processing within just 15 seconds in the abdomen and 60 seconds in the groin area. Moreover, the average level of destruction was left more than 3 Log 4 log respectively six hours after treatment compared with baseline levels in SOME areas of the groin and abdomen. In addition, the calculation of the 95% confidence interval of the data obtained after processing as the groin and the abdomen of the test composition, revealed that the lower boundary of the 95% confidence interval exceeds the level required by the 1994 FDA TFM.

Therefore, as described in more detail in the examples, the test composition is not only achieves immediate destruction after treatment (i.e. measured directly after drying, the treated area of the skin after application of the test composition), which corresponds to the lower limit of the boundaries presented by the FDA in 2005, and not only microorganisms can not recolonizing treated surface of the skin to the original level within six hours after treatment and, but the population of microorganisms can not grow to any significant amount during such six-hour period from their level 10 minutes after the treatment. It is surprising and unexpected result and provides indisputable proof that the tested composition continues to have a strong antimicrobial effect against the growth of microorganisms for at least six hours after treatment. Moreover, it was found that the tested composition meets and exceeds the 10-minute requirement 1994 FDA TFM directly after treatment and meets and exceeds the 6-hour requirements, even when it is applied on the treated skin surface in one motion, providing, thus, a much faster process. This fact demonstrates exceptionally strong antimicrobial activity of such compositions. Therefore, the test composition is not only significantly outperforms the standard FDA 10 minutes after the treatment, but is unexpectedly rapid effect and unexpectedly strong resistance even when applied quickly and in very small quantities. Moreover, the unexpectedly strong antimicrobial effect is achieved by using a combination of ingredients that are well tolerated by the skin of patients and medical lane is anal. Indeed, the rubbing test composition into the skin for two minutes does not cause visible redness or irritation.

In one embodiment, the antimicrobial composition contains the following main ingredients: alcohol, organic acid, at least one paraben, and the redox compound. In addition, the composition has a pH from about 3 to about 7. Provided that the composition contains an acid, the composition may also include an ingredient that acts in solution as the pH regulator, if necessary bringing the pH in the range from approximately 3 to approximately 7. In one embodiment, the pH regulator is an organic acid. As described below, the antimicrobial composition may include ingredients in addition to the basic ingredients.

In one embodiment, the alcohol has a quick antimicrobial properties and facilitates dissolving or dispersing therein other components. In another embodiment, the alcohol is an alcohol With1-C6. As used in the present description, "C1", "C2", "C3", "C4", "C5" and "C6" refers to alcohols having one, two, three, four, five or six carbon atoms, respectively. The location of carbon atoms such sleep is tov may be branched or linear. In yet another embodiment, the alcohol is a lower alcohol, such as alcohol1-C4. Examples of lower alcohols include methanol, ethanol, propanol and butanol, as well as their isomers and mixtures. In a particular embodiment, the alcohol is isopropyl alcohol, which is also known as 2-propanol or isopropanol.

In one embodiment, the implementation of the alcohol concentration in the antimicrobial composition comprises at least 30 percent by weight calculated on the total weight of the antimicrobial composition. For example, in one of the embodiments the antimicrobial composition comprises from about 30 percent to about 85 percent by weight of alcohol. In various embodiments, the implementation of the alcohol concentration in the antimicrobial composition is at least about 35 percent by weight. For example, in one of the embodiments the antimicrobial composition comprises from about 35 percent to about 85 percent by weight of alcohol. In another embodiment, the alcohol concentration in the antimicrobial composition comprises at least about 40 percent by weight. For example, in one of the embodiments the antimicrobial composition comprises from about 40 percent to about 85 percent by weight of alcohol. In yet another variant on the westline the alcohol concentration in the antimicrobial composition comprises at least about 45 percent by weight. For example, in one of the embodiments the antimicrobial composition comprises from about 45 percent to about 75 percent by weight of alcohol. In yet another embodiment, the alcohol concentration in the antimicrobial composition comprises at least about 50 percent by weight. For example, in one of the embodiments the antimicrobial composition comprises from about 50 percent to about 75 percent by weight of alcohol. In yet another embodiment, the alcohol concentration in the antimicrobial composition is at least about 55 percent by weight. For example, in one of the embodiments the antimicrobial composition comprises from about 55 percent to about 75 percent by weight of alcohol. In another embodiment, the alcohol concentration is approximately 60 percent by weight. For example, in one of the embodiments the antimicrobial composition comprises from about 60 percent to about 70 percent by weight of alcohol. In another embodiment, the alcohol concentration is at least about 65 percent by weight. In yet another embodiment, the alcohol concentration is at least about 70 percent by weight. Additionally, in other alternativehealth the implementation of the concentration of alcohol is chosen from one of the following: at least about 75 percent by weight; at least about 80 percent by weight and at least about 85 percent by weight.

The antimicrobial composition may also contain alternative quantities of alcohol. For example, in one optional embodiment, the antimicrobial composition comprises from about 62 percent to about 68 percent by weight of alcohol. In a more particular embodiment, the antimicrobial composition comprises from about 63 percent to about 67 percent by weight of alcohol. Additionally provides other options amount of alcohol in the antimicrobial composition in addition to or instead of these, as indicated above.

Organic acid included in the antimicrobial composition may vary in certain embodiments of the invention. As used in the present description, the term "organic acid" is used to refer to organic compounds that can dissociate, giving hydrogen, and lower water pH below neutral (i.e. below pH 7). In one embodiment, the organic acid includes at least one functional group of a carboxylic acid. As used in the present description, the "functional group carboxylic acid" refers to a functional group having the structural formula COOH, Kotor is also known as the carboxyl group. Examples of organic acids with at least one functional group of carboxylic acid include carboxylic acid, formic acid, acetic acid, stearic acid, lactic acid, almond acid, acrylic acid, oleic acid, benzoic acid, citric acid, salicylic acid, tartaric acid, succinic acid, phthalic acid, malonic acid, methacrylic acid, oxalic acid, solomonow acid, crotonic acid, glyceric acid, p-toluene acid, propanoic acid, heptane acid, butane acid, Castronovo acid, nitrocresol acid, zanoxolo acid, methoxybutanol acid, florexpo acid, Chloroacetic acid, bromoxynil acid, dichloracetic acid, glutaric acid, trichloroacetic acid, malic acid, hexanoic acid, trimellitic acid, timesyou acid, Aconitum acid, tricarballylic acid and gallium acid. In another embodiment, the organic acid includes three functional groups carboxylic acid. Examples of organic acids with three groups of carboxylic acids include citric acid, solomonow acid, trimellitic acid, timesyou acid, tricarballylic acid, Aconitum acid and mixtures thereof. Definitely the embodiment, the organic acid is citric acid.

In one embodiment, the antimicrobial composition comprises from about 1.5 percent to about 15 percent by weight organic acids. In another embodiment, the antimicrobial composition comprises from about 1.5 percent to about 13 percent by weight organic acids. In yet another embodiment, the antimicrobial composition comprises from about 1.5 percent to about 11 percent by weight organic acids. In another embodiment, the antimicrobial composition comprises from about 1.5 percent to about 9 percent by weight organic acids. In yet another embodiment, the antimicrobial composition comprises from about 1.5 percent to about 8 percent by weight organic acids. In yet another embodiment, the antimicrobial composition comprises from about 1.5 percent to about 7 percent by weight organic acids. In another embodiment, the antimicrobial composition comprises from about 1.5 percent to about 6 percent by weight organic acids. In an additional embodiment, the antimicrobial composition comprises from about 1.5 percent to about 5 percent by weight organic acids. In other variations is the implementation of the antimicrobial composition comprises from about 1.5 percent to about 4 percent by weight organic acids. In yet additional embodiments, the implementation of the antimicrobial composition comprises at least about 2 percent by weight organic acids. In yet another embodiment, the antimicrobial composition comprises at least about 3 percent by weight organic acids. In yet another embodiment, the antimicrobial composition comprises at least about 4 percent by weight organic acids. In an additional embodiment, the antimicrobial composition comprises at least about 5 percent by weight organic acids. In another embodiment, the antimicrobial composition comprises from about 5.5 to about 7.5 percent by weight organic acids. In yet another embodiment, the antimicrobial composition contains from about 6 percent to about 7 percent by weight organic acids. In yet another embodiment, the antimicrobial composition comprises about 4.6 percent by weight of citric acid. Also, the present invention also provides a different amount of organic acid in addition to or instead of the above.

As indicated above, the antimicrobial composition also contains at least one paraben. As used in the present description, the term "p the Raben" refers to alkyl ether, p-hydroxybenzoic acid. Examples of parabens include methylparaben, ethylparaben, propylparaben, butylparaben, and mixtures thereof. In one embodiment, the antimicrobial composition comprises methylparaben. In another embodiment, the antimicrobial composition contains propylparaben. In yet another embodiment, the antimicrobial composition contains methylparaben and propylparaben. However, it is also provided that may use other parabens or mixtures of parabens.

In one embodiment, the antimicrobial composition contains up to about 0.6 percent by weight of the paraben(s). In another embodiment, the antimicrobial composition comprises from about 0.01 percent to about 1 percent by weight of the paraben(s). In yet another embodiment, the antimicrobial composition comprises from about 0.01 percent to about 0.6 percent by weight of the paraben(s). In yet another embodiment, the antimicrobial composition comprises from about 0.01 percent to about 0.5 percent by weight of the paraben(s). In yet another embodiment, the antimicrobial composition comprises from about 0.05 percent to about 0.4 percent by weight of the paraben(s). In yet another embodiment, the antimicrobial composition comprises from about 0.1 percent to about 0.35 procento weight of the paraben(s).

In additional more specific embodiment, the antimicrobial composition contains up to about 0.4 percent by weight of methylparaben and up to about 0.2 percent by weight of propyl paraben. In yet another embodiment, the antimicrobial composition comprises from about 0.1 percent to about 0.4 percent by weight of methylparaben and from about 0.01 percent to about 0.2 percent by weight of propyl paraben. In yet another embodiment, the antimicrobial composition comprises from about 0.15% to about 0.35% by weight of methylparaben and from about 0.01 percent to about 0.2 percent by weight of propyl paraben. In another embodiment, the antimicrobial composition comprises from about 0.2 percent to about 0.3 percent by weight of methylparaben and from about 0.01 percent to about 0.2 percent by weight of propyl paraben. In yet another embodiment, the antimicrobial composition comprises from about 0.1 percent to about 0.4 percent by weight of methylparaben and from about 0.05 percent to about 0.15 percent by weight of propyl paraben. In another embodiment, the antimicrobial composition comprises from about 0.15% to about 0.35 percent by mA the of CE of methylparaben and from about 0.05 percent to about 0.15 percent by weight of propyl paraben. In an additional embodiment, the antimicrobial composition comprises from about 0.2 percent to about 0.3 percent by weight of methylparaben and from about 0.05 percent to about 0.15 percent by weight of propyl paraben.

The antimicrobial composition also contains a redox compound. For the purposes of the present invention, the term "redox" is a shorthand term used to denote a compound that can participate in the oxidation reaction/recovery, in which atoms change their oxidation state. "Recovery" refers to the reduction of the oxidation state of a molecule, atom or ion or, in some cases, the set of electrons, and "oxidation" refers to the increase in the degree of oxidation of a molecule, atom or ion or, in some cases, the loss of electrons. While the restoration of a molecule, atom or ion is caused in some cases by a set of one or more electrons, the oxidation of a molecule, atom or ion is called in some circumstances, the loss of one or more electrons, the change in the degree of oxidation does not always occur as a result of electron transfer. In the tested compositions described in the examples, the redox compound is methylene blue. Without limiting this image is the shadow of any theory or mechanism, which results, methylene blue shows additional chemical properties, which allegedly involved in his action in the antimicrobial composition. For example, methylene blue is a cationic compound, which probably causes the affinity of methylene blue molecules to the bacterial membranes, which are negatively charged, thus causing the Association of methylene blue with bacterial membranes, where its redox potential provides antimicrobial effect due to changes in the permeability of the membranes and the respiratory function of bacterial cells. In other embodiments, implementation of the present invention redox compound comprises a cationic redox compound. Another characteristic of methylene blue is that it shows photosensitivity, and therefore it is called the "photosensitizer". The photosensitizer is a chemical compound that readily undergoes photoexcitation when exposed to light and then is able to transfer its energy to other molecules in the mixture or solution, making, thus, the mixture or solution is more sensitive to the chemical reactions involved, for example, in the production of superoxide or atomic is ikorodu. While the photosensitivity of the redox compound is not considered critical for the action of the antimicrobial composition, photosensitizing compound provides a reservoir of energy in the antimicrobial composition, it was found that the application of light of a suitable wavelength enhances the antimicrobial efficacy of the antimicrobial composition, which contains photosensitizing redox compound. Without limitation to any theory believe that the photosensitizing redox compound exhibits a photoinduced electron transfer. In one embodiment, the present invention redox connection comprises a photosensitizing redox compound, such as, for example, phenothiazine dye, Riboflavin and the like. In yet another embodiment, the redox compound comprises photosensitizing cationic redox compound. Examples of redox compounds suitable for inclusion in the antimicrobial composition include, for example, but without limitation, methylene blue, methylotrophy blue, dimethylmethylene blue assay, azure a, azure b, azure C, thionin, toluidine blue, methylene is yellowy, Riboflavin, brilliant crystal blue, proflavin, as well as other dyes, such as, for example, rose Bengal, hypericin, methylene violet, rivanol, acriflavin, trypan blue, neutral red, methylene green, acridine orange, and mixtures thereof. In one embodiment, the redox compound comprises methylene blue. In yet another embodiment, the antimicrobial compositions include a photosensitizing compound in addition to the redox connection.

In one embodiment, the antimicrobial composition contains up to about 0.2 percent by weight redox compounds. In yet another embodiment, the antimicrobial composition comprises from about 0.01 percent to about 0.2 percent by weight redox compounds. In yet another embodiment, the antimicrobial composition comprises from about 0.01 percent to about 0.15 percent by weight redox compounds. In another embodiment, the antimicrobial composition comprises from about 0.03 percent to about 0.12 percent by weight redox compounds. In another embodiment, the antimicrobial compositions which s contains from about 0.03 percent to about 0.1 percent by weight redox compounds. In an additional embodiment, the antimicrobial composition comprises from about 0.03% to about 0.09% by weight redox compounds. In another embodiment, the antimicrobial composition comprises from about 0.03% to about 0.08 percent by weight redox compounds. In another embodiment, the antimicrobial composition comprises from about 0.04% to about 0.07 percent by weight redox compounds. In another embodiment, the antimicrobial composition comprises from about 0.04% to about 0.06 percent by weight of the oxidation-vosstanovitelnogo connection.

In one embodiment of the invention, the redox compound is of a type that is effective for pigmentation or coloring the skin surface, on which is applied antimicrobial composition. In another embodiment, in which in addition to the redox compound is present photosensitizing compound, one or both of the photosensitizing compounds and redox compounds are effective for pigmentation or coloring the surface of the skin, the cat is the ROI is applied antimicrobial composition. Therefore, the person responsible for applying the antimicrobial composition can easily understand, was there a certain area on the surface of the skin treated antimicrobial composition. Moreover, in some embodiments, the implementation of the intensity of the color on the skin can be an indicator of the duration of time that has passed since the processing surface of the skin antimicrobial composition.

The antimicrobial composition also optionally contains a pH regulator, if it is necessary or desirable to reduce the pH of the composition. In one embodiment, the pH regulator includes a basic salt, such as, for example, the main organic salt. As used in the present description, the term "basic salt" refers to a compound in which the hydrogen of the acid is replaced by a metal or its equivalent, and which increases the water's pH above neutral (i.e. above pH 7.0). In one embodiment, the basic salt is selected for inclusion in the antimicrobial composition is an organic salt that has the same organic component, and an organic acid, providing, thus, the system of the acid/salt based on the same organic anion. In another embodiment, the organic salt has a type other than organic acids. In one embodiment, the organic is Oh salt is a citrate salt. In another embodiment, the organic acid is citric acid and the organic salt is a citrate salt. Examples of citrate salts include, but are not limited to, sodium citrate, dihydrate of trisodium citrate, dihydrate sodium citrate, potassium citrate, lithium citrate, and mixtures thereof. In one specific embodiment, citrate salt is sodium citrate. In another embodiment, citrate salt is a dihydrate of trisodium citrate.

In one embodiment of the invention, the antimicrobial composition comprises about 1 percent by weight of basic organic salt. In yet another embodiment, the antimicrobial composition comprises from about 0.1 percent to about 0.9 percent by weight of basic organic salt. In yet another embodiment, the antimicrobial composition comprises from about 0.2 percent to about 0.9 percent by weight of the main organic acids. In an additional embodiment, the antimicrobial composition comprises from about 0.2 percent to about 0.8 percent by weight of basic organic salt. In another embodiment, the antimicrobial composition comprises from about 0.3% to about 0.7% by weight of a basic organic salt. In another embodiment, Khujand the exercise of the antimicrobial composition comprises from about 0.4% to about 0.6 percent by weight of basic organic salt. Also provides that the antimicrobial composition may contain a number of basic organic salt that is different from the one described.

In one embodiment, the antimicrobial acid has a pH from about 3 to about 8. In another embodiment, the antimicrobial composition has a pH from about 3 to about 7. In an additional embodiment, the antimicrobial composition has a pH from about 3 to about 6. In another variant implementation of the antimicrobial composition has a pH from about 3 to about 5. In another embodiment, the antimicrobial composition has a pH from about 3 to about 4. As will be obvious to the person skilled in the art, provided that the pH regulator may include acidic or basic agent for adjusting the pH of the antimicrobial composition.

In one embodiment of the present invention an alcohol-based antimicrobial acid contains an organic acid in a concentration of from about 1.5 percent to about 10 percent by weight calculated on the total weight of the composition. The antimicrobial composition has a pH from about 3 to about 8, and also contains at least one paraben, and the redox compound. In one embodiment, the antimicrobial composition which contains at least about 55 percent by weight of isopropyl alcohol.

The antimicrobial composition can also contain other pharmaceutically acceptable funds in addition to those described above. "Pharmaceutically acceptable" means that the funds are under medical opinion, suitable for use in contact with the tissues of humans and lower animals without unwanted toxicity, irritation, allergic response and the like and conform to acceptable value of benefit/risk. As an example, the antimicrobial composition can contain a vehicle, viscosity modifier or thickener for modifying the viscosity of the composition that is understandable to the person skilled in the art. With this type of means the viscosity of the composition can be changed in relation to the desired use of the composition. For example, in one embodiments, the viscosity can be modified to provide an antimicrobial composition that is able to constantly be on the patient's skin for a long time after initial application. Such a composition may, for example, be applied to the skin for the first time and washed off from the skin later, when the surgical procedure must begin, therefore, by increasing the ease of application of the composition.

As an additional example, the antimicrobial composition may contain one or more of a wide variety of additives that may be what turned off for pain relief and/or healing of the skin, to compensate for the drying action of alcohol and/or other reasons. For example, the composition may contain one or more of lanolin, methylcellulose and propylene glycol to improve the conditioning properties of the composition to the skin. It should be understood that the term "ml" refers to various forms of lanolin and its derivatives, including, for example, lanolin, lanolin oil, lanolin wax, lanolin alcohols, lanolin fatty acids, isopropylmalate, ethoxylated lanolin, ethoxylated lanolin alcohols, ethoxylated cholesterol, propoxycarbonyl lanolin alcohols, acetylated lanolin alcohols, linoleic lanolin alcohols, ricinoleic lanolin alcohols, acetate of lanolin alcohols, ricinoleate, acetate of ethoxylated alcohols-esters, hydrogenolysis of lanolin, ethoxylated hydrogenated lanolin and ethoxylated sorbitol lanolin. In another embodiment, the composition may contain one or more of the aloe, vitamin a, vitamin E, vitamin D, talc, calamine and kaolin. Additional ingredients that may not necessarily be included in the composition, are fragrances, dyes, preservatives, antibacterial agents, antifungal agents and moisturizers. Of course, this list does not limit us is Aasee the invention, but simply provides examples of additional ingredients that may be included in the composition.

As another example, the antimicrobial composition may contain one or more of a wide variety of additives that can be included to provide relief of pain and/or numbness of the skin surface in contact with her. For example, the composition may contain local anesthetics or aminoamides or aminopyrrolo type. Examples of amino esters include, for example, benzocaine, chloroprocaine cocaine, cyclomethycaine, dimethocaine/larocaine, propoxycaine, procaine/novocaine, proparacaine and tetracaine/amethocaine. Examples of amino acids include, for example, articaine, bupivacaine, kartikay, cinchocaine/dibucaine, etidocaine, levobupivacaine, lidocaine/lignocaine, mepivacaine, piperocaine, prilocaine, ropivacaine and trimekain.

Although in the present description is not discussed above, should be taken into account that, when applicable, the balance of the antimicrobial composition was produced using the water. Moreover, it is envisaged that the antimicrobial composition may be provided in any suitable form, such as a gel, liquid, foam, ointment or lotion, indicating only a few possibilities. The antimicrobial composition may be applied to the surface to be disinfected or area in any way. For example, on the nom embodiment, the antimicrobial composition is atomized spray or other propellant. In another embodiment, the antimicrobial composition can be sprayed with a suitable spray device, such as a manual pump bottled dispenser.

In another embodiment, the antimicrobial composition is first supplied to the applicator and then applied on the disinfected area. For example, with reference to figure 1 schematically illustrates the applicator 10. The applicator 10 includes an elongated handle 12 with the applicator 14 located at its end. The applicator portion 14 is formed of absorbent material that can hold a certain amount of antimicrobial composition to facilitate application of the antimicrobial composition to be disinfected the area. In one of the embodiments, for example, the applicator 14 is made of a cotton ball, rag, towel or sponge, indicating only a few possibilities. In one particular embodiment, the applicator shown in figure 2, the tampon 20 includes a handle 22 and a cotton applicator 24, located at the end of the handle. Cotton applicator 24 may be impregnated or saturated with an antimicrobial composition and then used for applying the antimicrobial composition to the surface to be disinfected or region.

In another embodiment of the applicator 10, the handle 12 includes a number antimicro the Noah song released from it on the applicator 14. For example, in one embodiment, the implementation of the antimicrobial composition is in the camera (not shown) of the handle 12, which is movably connected with at least part of the applicator 14 through holes (not shown). For example, fluid may pass from one chamber to the applicator 14 during actuation of the valve located between the chamber and the applicator 14. In one non-limiting embodiment of this example, the valve is an exhaust valve that opens to release at least part of the antimicrobial composition in the applicator 14, when the pressure of the antimicrobial composition in the chamber exceeds a predefined threshold. In this embodiment, it is contemplated that the handle 12 is elastically deformed, and the pressure of the antimicrobial composition in the cell generally corresponds to a pressure applied to the handle 12 by the user.

Also provides other types of applicators. For example, figure 3 shows a cross-section of the applicator 30, which includes the extension 32 and the porous applicator 46, located on the end of it. The extension 32 is generally hollow and hermetically closes the internal chamber 36 in which is located the container 38 is filled with an antimicrobial composition. The container 38 is made of XP is pogo material, which is destroyed in a certain part, apply localized pressure. Examples of fragile material include glass or certain types of plastic, meaning only a few possibilities. The applicator 30 also includes a lever 40, which is hinged to the extension 32 in any suitable manner. The lever 40 is able to exert pressure on the container 38, adjacent to the reduced thickness of the body 34 with the division 42 of the lever 40 when the lever 40 moves in the direction of the housing 32, as shown by the arrow A, until the destruction of the container 38, as illustrated in figure 3. When the container 38 is destroyed, the antimicrobial composition is released into the internal chamber 36 and comes into contact with a porous applicator 46, until it will become impregnated with the antimicrobial composition. In the illustrated embodiment, the membrane filter is located in the inner chamber 36 between the container 38 and the porous applicator 46 and is able to collect and prevent the passage of any of the destroyed particles from the container 38 to the porous applicator 46 with the antimicrobial composition. Membrane filter 44 may also be made to regulate the flow of the antimicrobial composition from the inner chamber 36 to the porous applicator 46. Although illustration is missing, it should be understood that other configurations can be used for destruction Conte is HEPA 38. For example, in one embodiment, the implementation of the applicator 30 includes a lever 40, and the casing wall 32 are deformed under the application of pressure to them efforts. When the casing wall 32 is compressed inside, they put pressure on the container 38 and destroy at least a portion of the container 38. In another variant implementation, the lever 40 is replaced by a pair of oppositely arranged wing-shaped parts, which are squeezed together with the destruction of the container 38. In another, napsoluciones.com embodiment, the housing 32 may include a sealed opening, which facilitates access to the camera 36 to replace the empty container 38 another container filled with an antimicrobial composition. Additionally or alternatively, provided that the applicator 30 may be destroyed after a single use. Additional details regarding the applicator, similar to the applicator 30, is presented in patent publication U.S. No. 2007/0248399, the contents of which are incorporated into this description by reference in its entirety. In yet another embodiment, the container 38 may be absent, and the antimicrobial composition may be contained in the inner chamber 36 before compressing force will exert pressure on the walls of the housing 32, in such a moment the antimicrobial composition passes through the valve and comes in contact with the porous applicator is 46.

Relative to figure 4, showing a packaged applicator 50, which includes a damp cloth 52. Moist cloth 52 is formed from an absorbent material that is saturated or impregnated with an antimicrobial composition. To prevent contamination wipes 52 and/or evaporation antimicrobial composition damp cloth 52 sterile sealed and placed in a packing 54 to use. If desired, the user can break the packing 54 along line 56, for example, to facilitate access to wet the cloth 52. As illustrated in figure 4, for example, part 58 are separated from the packing 54 and the portion 52a wipes 52 partially open, then as part 52b remains located in the package 54. Although not illustrated, it should be understood that the package 54 can be further broken along the line 56 and a damp cloth 52 may be completely removed from the package 54 to apply. Also it should be understood that the package 54 can be opened in any suitable manner that facilitates access and removing wet wipes 52 of the packing 54. Another applicator 60 in the form of pads 62 are shown in figure 5. The pad 62 is formed from an absorbent material that is saturated or impregnated with an antimicrobial composition. In one embodiment, the pad is formed of gauze material is. In another embodiment, the pad 62 includes a sponge. Similar with a damp cloth 52, the pad 62 may be sterile stoppered and placed in a packing 64 before use, to prevent contamination and/or evaporation. In the illustrative embodiment, the packing 64 is a package 66, which has an internal space 68, which is created for the maintenance of the pads 62. Package 66 includes resealable portion 69A, 69b, which remains closed until the pad 62 is taken out of the package 66 for use.

It is envisaged that the packing 54 and packing 64 can be formed from any material suitable for sterile hosting and providing access to wet the cloth 52 and the pad 62. In one particular embodiment, the packing 54, 64 are formed of a material suitable for heating, which prevents evaporation antimicrobial composition during heating. In this embodiment, the packing 54 and/or packing 64 can be heated to the desired temperature before damp cloth 52 and/or pad 62 out for use. In conclusion, damp cloth 52 and/or the pad 62 can be used with high temperature, where such a characteristic is desirable. For example, when damp cloth 52 and/or the pad 62 is heated, you can use disinfection of the patient's skin, while relaxing Vienna before intravenous access. As an additional object, in the absence of illustration, it should be understood that any one or more of the applicators 10, 20, 30 together with the applicator 70, described below, can be Packed similarly damp cloth 52 or the pad 62.

Another alternative implementation of the applicator 70 is illustrated in Fig.6. The applicator 70 includes a main portion 72 connected to the arm 74 and the scrubbing part 76. In one embodiment, the implementation of the cleaning portion 76 may be formed from an absorbent material, such as sponge, which is saturated or impregnated with an antimicrobial composition. In another embodiment, the cleaning portion 76 may include a number of bristles. In napsoluciones.com embodiment, the applicator 70 base 72 includes a reservoir for antimicrobial compositions that selectively released in the washer portion 76. In this embodiment, the user can apply an antimicrobial composition, if necessary, during the disinfection of the surface or area. Although not discussed above, it should be understood that the applicators 10, 20, 30, 50, 60, 70 can be provided without antimicrobial composition. In such applicators 10, 20, 30, 50, 60, 70 can be submerged in a tank containing the antimicrobial composition before application to a surface is the efficiency of the skin or can be used with an antimicrobial composition, put directly on the surface to be disinfected or region.

Also provides other types of applicators in addition to applicators 10, 20, 30, 50, 60, 70, including, but without limitation, rags, towels, cotton balls and sponge. In another embodiment, the applicator includes a plastic container with one or more of the flap, towels, gauze, gauze pads, cotton ball, cotton swab or sponge contained therein or otherwise attached thereto. In one particular embodiment, the applicator is suitable for heating before and/or after application to it of the antimicrobial composition. In another embodiment, the applicator is able to expose the antimicrobial composition to the action of light or other form of electromagnetic radiation prior to application of the composition to the skin surface. Also provide other options, representing the applicator and antimicrobial composition separately and then causing the antimicrobial composition on the applicator and/or disinfected surface or area.

The present invention also provides for a set of 80, schematically illustrated in Fig.7, for disinfecting a surface or area, such as the skin area of the patient. Set 80 is typically made for the storage and transportation of the applicator 84 and the container 6, which contains the antimicrobial composition. Set 80 includes the packing 82, including internal departments (not shown), which are usually made for the maintenance and protection of the applicator 84 and the container 86. It should be understood that the package 82 may be sterile sealed and place the applicator 84 and the container 86 to use. An alternative implementation of a set of 90 for disinfection schematically illustrated in Fig. Similarly, the set of 80 set 90 is usually made for the storage and transportation of the applicator 10, which already includes antimicrobial composition, absorbed by the applicator 14. Set 90 also includes the packing of 92, including internal departments (not shown), which are usually made for the maintenance and protection of the applicator 10. It should be understood that the packing 92 may be sterile sealed and place the applicator 10 in order to avoid contamination of the antimicrobial composition in the portion of the applicator 14 to the application. Not illustrated, but it should be understood that one or more of the applicators 10, 20, 30, 50, 60, 70 can be provided in sets 80, 90. Moreover, it is envisaged that one or both of the sets 80, 90 can include one or more medical or surgical tools, instruments and devices, including, for example, but not limited to, retractors, dilators, cuffs, Radiga the existing fabric, sutures, needles, syringes, scalpels, scissors, clamps, hemostatic tools, sponges, bandages, gloves, ointments, lubricants, antibiotics, painkillers and instructions for use.

In another embodiment, the method includes providing an alcohol-based antimicrobial compositions, the identification of the patient with a local presence of microorganisms in the place where the desired rapid eradication of microorganisms and sustainability kill germs for a long period of time, and the local application of an effective amount of an antimicrobial composition to the patient to quickly reduce the presence of microorganisms and maintain a reduced presence of microorganisms over an extended period of time. Examples of such locations include, for example, space operations, space wounds, broken skin, or other wounds, infected surface, including, for example, the surface of the nose or other mucous membranes and the like. The composition contains the organic acid concentration in the composition is from about 1.5 to about 10 percent by weight calculated on the total weight of the composition, at least one paraben and redox connection.

In yet another embodiment, the antimicrobial composition comprises alcohol at concentrations of at least about 60 PR is cent by weight; citric acid in a concentration of from about 4 percent to about 8 percent by weight; paraben at a concentration of up to about 0.6 percent by weight and the redox compound in a concentration of up to about 0.2 percent by weight. In another embodiment, the antimicrobial composition also contains a pH regulator, dispersed or dissolved in it. In yet another embodiment, the pH regulator include organic salt. In yet another embodiment, the pH regulator includes a citrate salt. In light of the unexpectedly strong antimicrobial effect of the test composition described in the present description, consider that the concentration of the ingredients can vary greatly, including antimicrobial effect, and such variations, which do not resolve the antimicrobial effect is widely available.

In another additional embodiment, the method includes the choice to be disinfected or being sanitized surface or area. After selecting the surface or area of the antimicrobial composition described in the present description, put on her. In one embodiment, the implementation of the area or surface represents the patient's skin and/or skin medical professional. In one particular embodiment, the region is the patient's skin,where it will be surgical procedure, or where through the protective layers of the skin of the patient to be implanted device for vascular access. In another specific embodiment, the region is the patient's skin that has open sores or wounds. In one particular embodiment, the method comprises applying an antimicrobial composition using gauze pads. In one embodiment of this variant implementation of the method includes securing gauze pads with absorbed antimicrobial composition, heating the antimicrobial composition and gauze pads and then processing or wash the patient's skin with gauze pads for the application of the antimicrobial composition, disinfecting, thus, the skin and extending Vienna before intravascular access. Gauze strip containing absorbed antimicrobial composition can be contained in the package prior to heating to prevent evaporation antimicrobial composition during heating.

In another embodiment, the method includes preoperative treatment region of the patient, which will carry out the operation, the antimicrobial composition described in the present description. The method also includes the avoidance of re-applying the antimicrobial composition to the surgical site over a long period of time during which the composition exhibits stability. In one embodiment, a long period is at least priblizitel is but up to two hours. In another embodiment, a long period of time is from about two hours to about four hours. In yet another embodiment, a long period of time is approximately four hours to about eight hours. In another embodiment, a long period of time is approximately eight hours to about twelve hours. In an additional embodiment, a long period of time is approximately six hours. In yet another embodiment, a long period of time is approximately more than ten hours. In another embodiment, the period of time is approximately 48 hours.

In yet another embodiment, a kit for preparation of the patient for a surgical procedure includes antimicrobial composition described in the present description. The set also includes at least one applicator for applying an antimicrobial composition to the skin surface of the patient. Examples of applicators include, for example, absorbent materials suitable for absorption of the antimicrobial composition. Examples include, but are not limited to, rags, towels, gauze, gauze pads, cotton balls, cotton swabs and devices comprising them. The present invention cover the t, that the antimicrobial composition may be loaded into the applicator immediately before use applicator for processing the surface of the skin. For example, the container antimicrobial compositions can be adapted for multiple doses, each of which can be enjoyed from the container to the applicator in the volume of a single dose for use in processing a certain area of the skin. Alternatively, the antimicrobial composition may be presented in a container containing a single dose, which can be loaded into the applicator before treatment area of the skin. As another variant implementation of the antimicrobial composition may be pre-loaded into the applicator and then Packed in a pre-loaded version. Because the antimicrobial composition comprises at least one volatile ingredient, packaging material is impervious to the ingredients of the composition. The invention also provides that the applicator can be constructed for heating the antimicrobial composition before applying them to the skin treatment. In another embodiment, the applicator containing the antimicrobial composition contained therein or absorbed therein, is located in the package and applicator together with the antimicrobial compositions are heated before applying the antimicrobial composition is in the place of skin treatment, for example, the site of the catheter, where it is desirable to destroy bacteria and expand blood vessels. In one embodiment, the applicator device designed for applying the antimicrobial composition to the surface of the nasal cavity of the patient. In another embodiment, the antimicrobial composition contains a redox compound which is effective for coloring or pigmentation of the skin surface on which it is applied.

The present invention also provides a method of inhibiting infection by sanitizing surfaces such as hands of the surgeon, implantable medical device, medical device, a wound or other surface that need to be sanitized. In accordance with the invention, such surface is subjected sanitized by washing, soaking, wiping, or otherwise contact the surface being sanitized, with local antimicrobial composition as described in the present description.

The following examples are included to provide additional description of the present invention. It should be understood that these examples are intended to be illustrative and non-limiting in nature.

Example 1

Antimicrobial composition was prepared in accordance with ISO what rutenium, containing the following concentrations of 70% isopropyl alcohol: 4,35% citric acid, 0.4% sodium citrate, 0.2% methylparaben, 0.1% propyl paraben and 50 mg% methylene blue. The target pH of the antimicrobial composition is 3.3.

Example 2

In accordance with the invention receive antimicrobial composition containing calculated on the total weight of the composition following concentrations: 66% isopropyl alcohol, a 4.9% citric acid, 0.45% of sodium citrate, 0,24% methylparaben, 0,11% propyl paraben and 0.007% methylene blue. The balance of the antimicrobial composition is water.

Example 3

In accordance with the invention receive antimicrobial composition containing calculated on the total weight of the composition following concentrations: 70% isopropyl alcohol, 4.6% of citric acid, 0.2% methylparaben, 0.1% propyl paraben and 0.05% methylene blue. The balance of the antimicrobial composition is water.

Example 4

One liter antimicrobial composition was obtained by adding and mixing 43,497 g of anhydrous citric acid and 4 g of sodium citrate with 900 ml of 70% isopropyl alcohol. The composition was additionally obtained by successive addition of 2 g of methylparaben, 1 g of propyl paraben and 0,584 g methylene blue (three-hydrate). After adding each ingredient of the composition are thoroughly mixed. Compliance is adequate amount of 70% isopropyl alcohol was then added to bring the total amount of the antimicrobial composition to one liter.

Example 5

Antimicrobial composition obtained as described in example 4 (referred to in this description as "studied composition"), was investigated to determine its effectiveness in vivo as a means for pre-processing. The purpose of this study (hereinafter in the present description "study 1") was to measure the functionality of the investigated compositions in terms of the criteria of the Food and Drug Administration's Tentative Final Monograph of June 17, 1994 (FR Notice Vol. 59, No. 116) for use as a preoperative medication (referred to in this description as "the 1994 FDA TFM").

1994 FDA TFM defines effective antimicrobial activity as equal to 2.0 log10reduce the average number of colony forming units (CFU) per square centimeter (cm2) the skin of the abdomen or equal to 3.0 log10reduce the average number of CFU/cm2inguinal skin 10 minutes after the treatment the skin with an antiseptic product. In addition, the average number of CFU/cm2the skin should remain below the initial amount within 6 hours after treatment. The FDA recently overestimated such performance criteria and "raised the bar" on the effect of destruction required from new preoperative preparations. For the test product to be effective according to the new requirements (referred to in this description the AI as "the requirements of the 2005 FDA"), lower bound 95% confidence interval for mean log reduction for the test product should be at least 2 log in the abdomen and 3 log in the groin area after 10 minutes, and then not to exceed the original six (6) hours.

Research area

The test composition was applied on the abdomen and groin patients using two-minute treatment each treated area of the skin, followed by drying for three minutes. Microbiological samples were obtained in three (3) different points in time relative to each treatment. To assess periods of time after processing, the term "treatment" is intended to refer to the entire period of time, which comprises applying the test composition on the surface of the skin (i.e. with a two-minute treatment in these circumstances), and the time required for drying the sample of the skin (i.e. through a three-minute drying in these circumstances). Therefore, the period of time measured from the processing or after processing"), begins after the drying time, which follows after application of the test composition. Three (3) different time periods, which received microbiological samples for each treatment are listed below:

(1) immediately before Nanase is receiving the test compositions (such a pattern is also referred to in this description as "original"),

(2) through ten (10) minutes (+/- 15 seconds) after processing

(3) through six (6) hours (+/- 30 minutes) after processing.

The study was performed according to the method specified in the 1994 FDA TFM. Between the sample in ten minutes and the sample after six hours of study area the abdomen and groin were covered with sterile gauze and a semi-permeable dressings.

Patients

A sufficient number of apparently healthy patients of either sex, any race, and at the age of at least eighteen (18) years were included in the study to provide at least fourteen (14) samples after treatment at each time point after treatment in each study site (abdomen, and groin). All patients without dermatoses, cuts, lesions, or other skin diseases on or around the test areas of the abdomen and groin (inguinal) were approached for participation in the study. Patients were included if the number of microorganisms in the tested samples was averaged 2.5 log10CFU/cm2the skin of the abdomen and 4.5 log10CFU/cm2the skin of the groin. All patients gave written informed consent before inclusion in the study.

Research design

The period prior to the study

Period of one (1) week (seven (7) days prior to the application of the product was identified as the period of "to study". During this time the patient is s instructed to avoid the use of healing soap, lotions, shampoos, deodorants and other, as well as skin contact with solvents, acids and alkalis. Patients are also instructed to avoid the use of tanning or swimming in antimicrobe processed (e.g., chlorinated) pools and/or Jacuzzi.

Patients could not shave or appelrouth wax treated anatomical region within five (5) days before the period prior to the study. Patients were instructed not bathing or taking a shower within seventy-two (72) hours prior to specimen collection.

The original samples and samples after treatment were analyzed by a computerized randomization scheme.

Results

The results of study 1 are presented graphically in figures 9-10 for the treated area on the abdomen and groin. As can be seen in figures 9 and 10, the test composition had reached the middle of the destruction of bacteria at time in ten minutes, which significantly exceeded the requirements established in 1994 FDA TFM, and the test composition showed excellent stability, preventing the recovery of microbial colonies within six hours after treatment. Figure 9 and 10 levels required by the 1994 FDA TFM, defined by horizontal bars marked "threshold FDA". As can be seen in figures 9 and 10, the test composition was shown effective rapid destruction, and exp is defined stability for at least six hours.

Example 6

The second study (hereinafter in the present description "study 2") was performed to (i) assess how quickly the test composition may reach the level of destruction of microorganisms, the desired 1994 FDA TFM, at time 10 minutes after the treatment, (ii) estimates of the lower limits of the 95% confidence interval in accordance with the requirements of the 2005 FDA and (iii) comparison of different methods of applying the test composition on the treated skin surface. In particular, the antimicrobial efficacy of the test composition when used as a preoperative preparation of the patient were analyzed after processing protocols, which used three (3) different forms of application in two (2) different areas of the skin, i.e. the skin of the groin and the skin of the abdomen. Indicators other than specifically described above, all other parameters of the study and the conditions were the same as described above in example 5.

Research area

The test composition was applied on the abdomen and groin, using three (3) forms of application in each location as follows:

Abdomen:(1) single pass
(2) processing within fifteen (15) the minutes and
(3) processing within thirty (30) seconds
The crotch area:(1) processing within thirty (30) seconds
(2) processing within sixty (60) seconds and
(3) processing within ninety (90) seconds

Samples of microorganisms received four (4) different points in time relative to each treatment. Four (4) different time periods, which received the samples of microorganisms relative to each variant of the processing is indicated below:

(1) prior to application of the test composition (this sample is also referred to as "source"),

(2) thirty (30) seconds after treatment,

(3) through ten (10) minutes after treatment and

(4) through six (6) hours after processing.

Studies were performed using the methods specified in the 1994 FDA TFM.

Randomization

Three (3) inguinal and three (3) abdominal forms of the test were evaluated by accident and bilateral patients by computer randomization scheme, so that one (1) test variant was used on one (1) side and another version of the test from the opposite side of the patient in each of the two (2) test the area of the (groin and stomach).

Results

The average results log destruction test 2 are presented graphically on 11-12. As seen in figure 11 and 12, the test composition was achieved immediate destruction (i.e. within 30 seconds after treatment), which exceeded the requirements of the 10-minute destruction of the 1994 FDA TFM, even when the test composition was applied only in the form of a 30-second treatment of the skin in the groin area (11) and in the form of a single application to the skin of the abdomen (Fig).

In the following tables 1 and 2 list the data 95% confidence interval for the tested configurations, including a 15-second application of the test composition on the abdomen and a 60-second application of the test composition in the groin.

Table 1
Abdomen - minimum log10reducing the 1994 FDA TFM=2,0
The application time=15 seconds; sample size=8
The lower 95% confidence limitAverageThe upper 95% confidence limit
Directly1,972,87of 3.77
10 minutes2,41 3,00to 3.58
6 hours2,372,973,57

Table 2
The crotch area - minimum log10reducing the 1994 FDA TFM=3,0
The application time=60 seconds; sample size=15
The lower 95% confidence limitAverageThe upper 95% confidence limit
Directly3,053,924,79
10 minutesof 3.564,375,19
6 hours3,133,854,57

The application time of 60 seconds and 90 seconds in the groin area meets the requirements of FDA 2005 3 log destruction with a lower bound of the 95% confidence interval directly after treatment (i.e., after drying) and after 10 minutes, and the application time of 15 seconds and 30 seconds in the abdomen meets the requirements of FDA 2005 2 log destruction of the lower g is the banks 95% confidence interval immediately after processing and after 10 minutes.

In addition, as shown in tables 1 and 2, log destruction after 6 hours compared to baseline was within the 95% confidence interval log destruction after 10 minutes for each of the forms referred to in the present description, showing no significant recovery of bacteria in areas of skin treatment that significantly exceeds the requirements of the 1994 FDA TFM and requirements of FDA 2005.

Speed immediate destruction by local antimicrobial composition is extremely important especially in the operating room where the surgery can be critical. Unexpected and surprising efficacy of the test composition directly after drying, provides surgical efficiency and faster start of the operation, than with many other products that require a delay to achieve maximum efficiency, usually regarded as 10 minutes after application in damp places such as the groin. So, together with the almost complete destruction of bacteria there are amazing results that are unexpected in the light of the prior art.

Any theory, mechanism of action, evidence or discoveries presented in the present description, means more in-depth understanding of the present invention and are not intended to make the present invention in any way dependent upon such theory, mechanism of action, evidence or discoveries. It should be understood that although the use of the word preferable, preferably or predominantly in the above description indicates that marked as such characteristics may be more desirable, however, this is optional, and embodiments of, no, may be provided for displacement of the invention, which is defined by the following claims. When reading the claims is intended that when in the present description uses words such as singular, "at least one", "at least part" there are no restrictions on claims by only one point, if not specifically stated otherwise in the claims. Additionally, when using the expression "at least part" and/or "part", the term may include a portion and/or the whole thing, if not specifically stated otherwise. Although the invention has been illustrated and described in detail on the figures and the above description, it should be considered as illustrative and non-limiting in nature, it should be understood that there were shows and describes only selected embodiments of and that all changes, modifications, and equivalents that fall within the scope of the invention as defined in the present description is in any of the following claims, preferably are protected.

1. Antimicrobial composition containing:
(a) at least about 30 wt.% by mass or more C1-C6alcohol;
(b) from about 1.5 wt.% to about 15 wt.% citric acid;
(c) from about 0.01 wt.% up to 1 wt.% paraben-free; and
(d) from about 0.01 wt.% to 0.2 wt.% redox compounds;
where the antimicrobial composition has a pH from about 3 to about 7.

2. The antimicrobial composition according to claim 1, where the composition comprises at least about 30 wt.% isopropyl alcohol.

3. The antimicrobial composition according to claim 1, where the composition comprises at least about 55 wt.% isopropyl alcohol.

4. The antimicrobial composition according to claim 1, where the specified organic acid contains at least about 3 wt.% up to 8 wt.% citric acid.

5. The antimicrobial composition according to claim 1, where the specified paraben selected from the group consisting of methyl paraben, propyl paraben, ethylparaben and butylparaben.

6. The antimicrobial composition according to claim 1, where the specified composition contains methylparaben at a concentration of from about 0.1 percent to about 0.4 wt.% and propylparaben at a concentration of from about 0.01 wt.% to 0.2 wt.%.

7. The antimicrobial composition according to claim 1, where the specified Oka the long-restorative connection comprises a cationic compound.

8. The antimicrobial composition according to claim 1, where the specified redox connection comprises a photosensitizing redox connection.

9. The antimicrobial composition according to claim 1, where the specified redox compound includes phenothiazine dye.

10. The antimicrobial composition according to claim 1, where the specified redox compound contains methylene blue.

11. The antimicrobial composition according to claim 1, where the specified redox compound selected from the group consisting of rose Bengal, hypericin, methylene violet, proflavine, Riboflavin, rivanol, acriflavine, toluidine blue, Trypanosoma blue, neutral red, d-methyl, azure a, azure b, methylene green, dimethylmethylene blue assay, acridine orange, and mixtures thereof.

12. The antimicrobial composition according to claim 1, where the specified redox compound comprises methylene blue, and the concentration of methylene blue in the composition is from about 0.03 percent to about 0.12 wt.%.

13. The antimicrobial composition according to claim 1, additionally containing the pH Adjuster.

14. The antimicrobial composition according to claim 1, additionally containing basic organic salt.

15. The antimicrobial composition according to 14, where asanoi basic organic salt is a citrate salt.

16. The antimicrobial composition according to item 15, where the specified citrate salt is sodium citrate, and the concentration of citrate in the composition is from about 0.2 wt.% to about 0.9 wt.%.

17. The antimicrobial composition according to claim 1, where the specified composition is able to achieve 2 Log destruction in the treated area of the skin of the abdomen and 3 log destruction in the treated area inguinal skin immediately upon application of a specified composition on the specified processing of the abdominal skin and the skin of the groin.

18. The antimicrobial composition according to claim 1, containing:
(a) C1-C6alcohol in a concentration of at least about 30 wt.%;
(b) citric acid in a concentration of from about 4 wt.% to about 8 wt.%;
(c) paraben at a concentration of up to about 0.6 wt.%; and
(d) methylene blue in a concentration of up to about 0.2 wt.%;
where the antimicrobial composition has a pH from about 3 to about 7.

19. The antimicrobial composition according p where specified parabens include methylparaben at a concentration of up to about 0.4 wt.% and propylparaben at a concentration of up to about 0.2 wt.%.

20. The antimicrobial composition according p additionally contains citrate salt, dissolved or dispergirovannoyj it.

21. The antimicrobial composition according to claim 1, where the composition comprises (a) at IU is greater least about 30 wt.% or more C 1-C6alcohol, (b) from about 4 wt.% to about 8 wt.% citric acid, (c) from about 0.1 wt.% up to about 0.4 wt.% the methylparaben and from about 0.01 wt.% up to about 0.2 wt.% of propyl paraben, (d) from about 0.03 wt.% up to 0.09 wt.% methylene blue, and (e) from about 0.2 wt.% to about 0.9 wt.% sodium citrate.

22. The antimicrobial composition according to claim 1, where the composition comprises at least about 60 wt.% isopropyl alcohol.

23. The antimicrobial composition according to item 21, where the composition comprises at least about 60 wt.% isopropyl alcohol.

24. The antimicrobial composition according to any one of claims 1 to 23 for reducing micro-organisms present on the skin or to disinfect open wounds of soft tissues.

25. The way to reduce micro-organisms present on the skin, comprising applying an effective amount of a composition according to any one of claims 1 to 23 on the surface of the skin of the patient to reduce the presence of microorganisms.

26. The method according A.25, where the specified application includes:
providing an applicator comprising an absorbent material bearing sorbed on him antimicrobial composition according to any one of claims 1 to 24, and
processing the surface of the skin the composition within about sixty seconds.

27. The method according to claim 2, additionally comprising prior to the specified heat treatment applicator and composition absorbed therein.

28. The way po, where the specified application includes processing the surface of the skin composition for up to approximately thirty seconds.

29. The method according to p. 25, further comprising providing the surface of the skin to dry.

30. The way to reduce microorganisms present on mucous membranes, comprising applying an effective amount of a composition according to any one of claims 1 to 23 on the mucosal surface of the patient to reduce the presence of microorganisms.

31. Way to disinfect open wounds of soft tissues, including wound cleansing effective amount of a composition according to any one of claims 1 to 23 for the disinfection of wounds.

32. Method for disinfecting surgical instruments, including
the provision of a liquid bath, comprising the antimicrobial composition according to any one of claims 1 to 23; and
immersion of a surgical instrument into a liquid bath to disinfect the instrument.

33. The applicator includes
(a) adsorbing material and adsorbed on him antimicrobial composition according to any one of claims 1 to 23; or
(b) adsorbing material and the handle containing the amount of the antimicrobial composition according to any one of claims 1 to 23.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to field of cosmetology and represents preparation for decolouration of keratin fibres, characterised by the fact that it contains in cosmetic carrier: i) at least one cationic derivative of 2-acylpyridinium of formula , where R is alkyl group with the number of C atoms from 1 to 4, R1 is alkyl group with the number of C atoms from 1 to 6, R2 is hydrogen atom, X is physiologically acceptable anion, ii) at least one anionic surface-active substance, selected from sulfates of alkyl ethers, corresponding to formula (II) R"-(OC2H4)n-OSO3M, where R" is linear or branched saturated or unsaturated alkyl chain with the number of C atoms from 8 to 30, n is a number larger than 2 and M is proton or physiologically acceptable cation, and iii) hydrogen peroxide or solid product of hydrogen peroxide binding to inorganic or organic compounds.

EFFECT: method provides stronger decolouration of keratin fibres than application of comparable amount of hydrogen peroxide alone, which makes it possible to reduce amount of applied oxidiser and reduce damage to hair to minimum.

10 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a non-aqueous composition of a tooth powder containing: a) at least one gum specified in a group consisting of carragheenan and carboxymethyl cellulose gums in an amount of 0.5 wt % to 5.0 wt %; b) at least one humidifier in an amount of 20.0 wt % to 80.0 wt % and c) biologically acceptable and biologically active glass representing mixed particles having a size of less than 20 mcm to less than 1 mcm and particles having a size of less than 90 mcm to less than 20 mcm in an amount of 1.0 wt % to 20.0 wt %.

EFFECT: invention provides creating the product containing biologically acceptable and biologically active glass that possesses stability and acceptable taste.

18 cl, 3 ex, 3 dwg, 5 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to film-generating composition capable of spreading. Composition is formed from water emulsion, which contains (I) particles with colloid silicon dioxide core with silicone envelope, consisting of (a) from 90 wt % to 10 wt % of colloid silicon dioxide cores and (b) from 10 wt % to 90 wt % of polyorganosiloxane envelopes; (II) polyalkylene oxide-modified trisiloxane; (III) complex of emulsifiers, consisting of, at least, one anionic surface-active substance; and (IV) salt of acidic polymerisation catalyst. Composition is included into emulsion or film. Composition can include optional ingredients, acceptable for personal hygiene, hair care, skin care, agricultural application and for house care. Invention makes it possible to realise said purpose.

EFFECT: obtaining film-generating composition capable of spreading.

21 cl, 6 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: disclosed is a vesicle-containing composition which is characterised by that it contains: (A) a silicone-based surfactant which is silicon modified with polyoxyalkylene, (B) one or more anionic surfactants selected from polyoxyethylenealkyl(12-15)ether-phosphate, acylmethyltaurate and acylglutamate in amount of 0.001-0.2 wt %, (C) polar oil having IOB of 0.05-0.80 and/or silicone oil, and (D) water, which contains a water-soluble medicinal agent, in amount of 0.5-5 wt % of the weight of the composition, where the silicone-based surfactant (A) forms vesicles; the anionic surfactant(s) (B) is attached to the surface of the vesicles; and the polar oil and/or silicone oil (C) is present inside the bilayer membrane of the vesicles.

EFFECT: disclosed composition has excellent stability even in the presence of high concentrations of a water-soluble medicinal agent.

6 cl, 8 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a composition of a teeth care preparation, which contains amorphous quartz, with size particles, characterised by the fact that D90 constitutes less than approximately 50 microns, and a source of peroxides, with BET surface area of amorphous quartz being in the range from approximately 1 m2/g to approximately 50 m2/g.

EFFECT: improvement of the composition.

11 cl, 2 ex, 30 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to biomedical compositions and methods of treating skin-affecting diseases, disorders and states.

EFFECT: compositions and methods of treating skin states, resulting from production of active forms of oxygen in a subject's skin, include application of local composition, containing an antioxidant compound with a lipophilic, mitochondria targeted cation, and which delivers therapeutically efficient quality of the antioxidant compound to fibroblasts and keratocytes of the skin.

13 cl, 2 tbl, 3 ex, 4 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and discloses an anhydrous liquid antiperspirant composition containing: a) a carrier containing i) at least one component selected from a cation and a zwitterion, and ii) a hydrogen bond donor, where content of the carrier is higher than content of any other substance in the composition, and the cation and/or zwitterion and hydrogen bond donor form a eutectic solvent; b) at least one active substance with antiperspirant activity, where the cation/zwitterion is at least one substance selected from trimethylglycine, trimethylglycine hydrochloride, glycine, amino acids and choline chloride, and where the hydrogen bond donor contains urea.

EFFECT: invention enables to produce a transparent antiperspirant which does not leave white marks when applied onto the skin of the consumer and has high stability.

16 cl, 18 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to a composition, possessing immunomodulating and anti-inflammatory properties. The dermatological composition, possessing immunomodulating and anti-inflammatory properties, as an active ingredient, contains an extract of the aboveground part/parts of oat, collected before ear formation. The cosmetic composition, possessing immunomodulating and anti-inflammatory properties. Application of the extract of the aboveground part/parts of oat, collected before ear formation, possessing immunomodulating and anti-inflammatory properties, as a medication.

EFFECT: composition and extract possess expressed immunomodulating and anti-inflammatory properties.

15 cl, 1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compositions of teeth care preparations. The claimed composition contains cation-modified silicon dioxide in quantity from 0.01 wt % to 30 wt % of the composition weight, where cation-modified silicon dioxide contains silicon dioxide, covalently bound with positively charged peptide, or where cation-modified silicon dioxide contains silicon dioxide, covalently bound with silane, where silane contains the primary and secondary aminogroup, and their combinations. The composition is preferably made in a form of toothpaste. As positively charged peptide polylysin can be applied, as silane - (3-aminopropyl)-triethoxysilane, (3-aminopropyl)-diethoxy-methylsilane, (3-aminopropyl)-dimethyl-ethoxysilane and their combinations.

EFFECT: composition is capable of precipitating on the teeth surface and providing a chemical barrier, in such a way preventing or eliminating damage to teeth enamel and ensuring remineralisation of teeth.

11 cl, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to a teeth bleaching composition, which includes (i) in fact, a water-insoluble and in fact indestructible component of a polymer matrix, which is capable of tight connection with the tooth surface, on condition that, if the component of the polymer matrix is in unsteady form, it can be subjected to solidification by chemical modification, where the claimed component of the matrix represents a vinyl-containing polymer, obtained from, at least, two types of monomers, each of which contains an acrylate group; and (ii) filled with gas, which includes air, carbonic gas, nitrogen, argon or their mixture, or liquid, which includes water, alcohol (for example, ethanol) or their mixture, pores, included in the said component of the polymer matrix, in which, at least, part of the said filled with gas or liquid pores has, at least, one value of size in the range from approximately 100 nm to approximately 5 mcm, and filled with gas or liquid pores and the component of the polymer matrix have difference in coefficient of refraction, at least, equal to 0.1.

EFFECT: composition improvement.

27 cl, 2 ex, 5 tbl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to dentistry and concerns preparing an oral care agent. For this purpose, a kit comprising an optically transparent composition containing a photosensitising dye, and a light-emitting device emitting light at a wave length and over a period of time sufficient to activate the photosensitising dye is presented. The above dye is specified in a group consisting of chlorophyllin sodium copper salt, tartrazin (FD&C yellow No.5), riboflavin-5'-monophosphate sodium salt, Allura Red AC (FD&C red No.40), new coccine (CI 16255, edible red 7), chromotrope FB (CI 14720, edible red 3), indigo carmine, erioglaucine disodium salt (FD&C blue No.1), fast green FCF (FD&C green No.3), lissamine green B, naphthol green or acid green, cochineal, carmoisine azorubin, amaranth, brilliant scarlet 4R, complexes of copper and chrolophyl, brilliant black BN (PN), chocolate brown HT, β-carotin, bixin, lycopene, betanin, Erythrosin B sodium salt and mixtures thereof. The optically transparent oral care composition contains a negligible amount of titanium dioxide and 3% or less of silicone dioxide.

EFFECT: invention provides effective treatment and/or prevention of conditions caused by microorganisms by creating strong antibacterial activity with non-toxicity and safety of the used dyes.

16 cl, 3 ex, 14 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to infectious diseases and immunology, and may be used for treating the patients with influenza and other influenza-like illnesses complicated with pneumonia. That is ensured by prescribing an antibacterial therapy and administering cytokine presented by interleukin-1β subcutaneously in a dose of 0.5…1.0 mcg, and then cytoflavin immediately after cytokine intravenously drop-by-drop in a dose of 5…10 ml once a day for four days.

EFFECT: method enables reducing the length of the clinical manifestations of influenza and influenza-like illnesses complicated with pneumonia, and forming protective immunity ensured by lowering the concentration of the anti-inflammatory cytokines and increasing blood serum circulating interferons with reducing side effects.

1 dwg, 7 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to medicine and specifically to trauma surgery and orthopaedics, and can be sued for surgical treatment of ununited fractures and false joints of cylindrical bones when there is a shortage of soft tissue. The method involves, 5-6 days before an operation, performing needle biopsy of bone and soft tissue fragments from the damage centre of the cylindrical bone and determining presence and nature of obligate intracellular viral infection (OIVI). Super-selective angiographic analysis of the microvascular channel to the capillary link is also performed. Valtrex is administered to the patient 2-4 days before the operation in a dose of 500 mg twice a day. Further, the method involves performing osteosynthesis or re-osteosynthesis with resection of the ends of bone fragments, opening marrowy canals, bone stimulation and batting the space of the bone defect with a gel-like nanostructured composite implant. In the presence of OIVI, resection of bone fragments is carried out in a larger volume until the onset of "pinpoint bleeding", i.e. to areas with satisfactory intrabone blood supply. The composite implant contains thrombocyte-rich autoplasma, mixed in ratio of 1:(1-2) with granules of a complex alloplastic preparation (CAP) based on hydroxyapatite which contains 50-60 wt % collagen. The composite implant also contains either 0.08-2.8 wt % colloidal solution of nanoparticles of zero-valent silver metal Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, or 5-12 wt % nanoparticles of said metals in dry form. The nanoparticles have size of 2-40 nm. A colloidal solution of said nanoparticles or colloidal nanoparticles of said metals in dry form is added to the CAP granules. Further, the prepared granules of the gel-like complex alloplastic preparation are laid in a selected ratio on the layer of thrombocyte-rich autoplasma, without mixing, for subsequent transfer into the bone defect space. In case of performing resection of bone fragments in a larger volume until the onset of "pinpoint bleeding", corticotomy is further performed on the cylindrical bone being operated on, with subsequent distraction of the bone regenerate using any existing method. Further, the bone fragments are repositioned, followed by metallo-osteosynthesis. Before wound suturing, the surface of the area with shortage of soft tissue in the projection of the ununited fracture and false joints is covered by a semi-permeable flexible plate made of the complex alloplastic preparation based on hydroxyapatite, which contains 50-60 wt % collagen. The plate has thickness of 0.25-1.2 mm. The surface area of the plate is 10-20% greater than the area with shortage of soft tissue in the corresponding projection. The part of the erythrocyte mass remaining from preparing the thrombocyte-rich autoplasma and the plasma are returned into the bloodstream of the patient by intravenously using a drip during the surgical procedure or in the early post-operation period. After the operation, valtrex is administered to the patient in a dose of 500 gm once a day for two weeks and then in a dose of 500 mg every other day for two weeks.

EFFECT: method provides reliable prevention of OIVI at a damage centre, normalisation of local microcirculation of blood, avoiding ischemic processes, and compensation for the shortening of the length of the limb of the patient being operated on while preventing weakening of the process of reparative osteogenesis and allergic reactions of the body.

6 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to ophthalmology, to preparations for the treatment and prevention of eye diseases, and may be used in visual impairment, development and progression of eye diseases, as well as for the prevention and maintenance therapy of oxular diseases. Substance of the invention consists in the fact that a therapeutic eye balsam is characterised by the fact that it contains the ingredients in ratio in grams per 100 g of the therapeutic eye balsam of the following formulation: Siberian fir extract - 48.540 g, 5% propolis extract - 10.000 g, 0.9% physiological saline - 38.540 g, neoselen (food supplement) - 0.971 g, vitamin B2 - 0.007 g, citric acid - 0.971 g, ascorbic acid - 0.971 g that promotes achieving the declared technical effect ensured by the given proportions. The presented balsam enables the higher clinical effectiveness in all the forms of ocular pathologies, provides the anti-inflammatory effect on the eye mucosa and cornea, as well as delivers a good result in the post-traumatic and post-operative treatment.

EFFECT: therapeutic eye balsam containing the natural ingredients in certain proportions provides the integrated therapeutic effect on the visual organs and has found use in a great number of grateful patients.

1 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely ophthalmology. The method involves a transepithelial corneal collagen crosslinking. That is preceded with a single bath electrophoresis with 1% riboflavin mononucleotide. That is ensured by an initial current of 0.2 mA to be increased gradually to 1 mA, at a pitch of 0.2 mA for 2 minutes. That is followed by an ultraviolet corneal exposure. The exposure is conducted at wave length 370 nm, power 3 mWt/cm2 and combined with instillation of a riboflavin solution. The solution contains 0.1% riboflavin mononucleotide and 20% dextran.

EFFECT: method provides more effective riboflavin delivery to the corneal stroma for one procedure providing the intraocular protection against ultraviolet light.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly ophthalmology, and may be used for treating corneal ulcer. That is ensured by the integrated treatment including the intake of Lymphomyosot 10 drops in 50-100 ml of water three times a day for three weeks; Traumel 1 tablet 3 times daily for three weeks sublingually; 10 subcutaneous 2.2 ml injections twice a week: Mucosa Compositum, Solidago Compositum, Coenzyme Compositum; 10 subcutaneous 2.2 ml injections of Traumeel every second day; eye instillations of Oculoheel, okulohelya, Mydriacyl and colloidal silver 2 drops 3 times a day for 10 days; sea buckthorn oil under the eyelid 3 times a day for 10 days; Solcoseryl ointment or gel in the conjunctival cavity until observing the complete epithelialisation, and also the radiotherapy course from the first day of treatment in a dose of 50 cGy daily, within 5 sessions. The severe corneal opacities require the additional 5 sessions of the repeated radiotherapy course in a dose of 500 cGy daily following the 5-session radiotherapy course in a dose of 50 cGy three months later.

EFFECT: method enables increasing or recovering the visual acuity ensured by ulcer epithelisation with no side effects.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be applied for treatment of keratoconus. For this purpose ablation of epithelial layer is performed. Funnel with internal diameter, which exceeds diameter of cornea, is placed on eyeball surface. After that, funnel is filled with 0.1% solution of riboflavin on 20% solution of dextran until the volume totally covering cornea surface. When solution volume decreases, it is periodically added into funnel, supporting constant volume of solution in funnel until cornea is saturated with riboflavin solution. After that, ultraviolet irradiation of cornea with wave length 365 nm is carried out for 30 minutes. Irradiation is accompanied with additional instillations of 0.1% solution of riboflavin on 20% solution of dextran on cornea each 2-3 minutes to support its concentration.

EFFECT: method ensures acceleration of cornea saturation with riboflavin, increasing treatment efficiency, makes subjective endurance of procedure tolerance easier, is simple in implementation.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a vitamin additive containing vitamin B1, vitamin B2, nicotinic acid, vitamin B6, biotin and pantothenic acid; and wherein the weight ratio of biotin to vitamin B1 makes 1:20 to 1:25; wherein the weight ratio of biotin to vitamin B2 makes 1:25 to 1:30; wherein the weight ratio of biotin to nicotinic acid makes 1:310 to 1:330; wherein the weight ratio of biotin to vitamin B6 makes 1:30 to 1:35; wherein the weight ratio of biotin to pantothenic acid makes 1:110 to 1:130.

EFFECT: invention provides increasing activity, reducing the environmental stress effects, improving immunity of an individual, reducing the cases, the length and severity of respiratory infections.

13 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, namely to pharmaceutical industry and deals with solid pharmaceutical composition, possessing high physical strength. Claimed invention also presents method of manufacturing solid pharmaceutical composition. Claimed pharmaceutical composition contains 7 varicoloured types of granules in form of capsule. Granules contain, wt %: nikotinamide 1-35; pyridoxine 0.1-8; calcium pantitenate 0.1-15, thiamin 0.1-30; tryptophan 1-30; tocoferol 0.5-5; ascorbic acid 0.1-50; 5-hydroxyanthranyl acid 0.01-10; Riboflavin 0.1-10; folic acid 0.1-6; cyanocobalomin 0.001-6; isoleucin 0.5-10; leucin 0.5-15; lysine 0.5-20; phenylalanine 0.1-5; threonine 0.1-5.0; valin 0.1-8.0; methionine 0.1-15; lactose 1-4.0; ergocalcioferol 1-95.0 and auxiliary substances for obtaining granules.

EFFECT: claimed composition possesses excellent properties of medication release and digectionin application composition possesses hepatoprotective hypolipidemic immunostimulating and normalising kidney activity action.

2 cl. 2 ex. 5 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pediatric neurology, and can be used for rehabilitation of neurological disorders in children in case of neuroinfections. For this purpose, at the background of adequate complex and pathogenetic therapy, parenteral introduction of actovegin in acute period of disease additionally from the first days of disease cytoflavin is introduced intravenously by drop infusion in dose 0.6 ml/kg or 10 ml per day for 3-5 days, elcar perorally in dose 70-100 mg/kg of weight per day for 3-4 weeks. In the period of early reconvalescence pantogam is additionally introduced perorally in dose 50-70 mg/kg of weight per day for 4 weeks. In case if multifocal affection of brain substance is present, gliatilin is introduced intravenously by drop infusion in dose 1 ml per 5 kg of body weight per day in combination with intramuscular introduction of ipidacrine in dose 5-15 mg per day for 7-10 days, after that gliatilin perorally in dose 50 mg/kg of weight per day together with ipidacrine inside in dose 1 mg/kg per day for 4 weeks.

EFFECT: method makes it possible to improve disease outcome due to reduction of frequency of residual neurological deficiency formation with reduction of term of hospital treatment.

3 ex

FIELD: veterinary medicine.

SUBSTANCE: preparation comprises glucose, sodium chloride, sodium carbonate and potassium chloride, calcium acetate or calcium lactate, ascorbic acid, iron sulfate, chloromycetin and phtalazol with the following ratio of the components, g/l aqueous solution: glucose - 30.0; sodium chloride - 9.0; sodium carbonate - 5.0; potassium chloride - 0.2; calcium acetate or calcium lactate - 1.0; ascorbic acid - 0.5; iron sulfate - 0.2; chloromycetin - 1.0; phtalazol - 1.0.

EFFECT: preparation has high therapeutic and prophylactic efficacy in case of gastrointestinal diseases of newborn calves.

2 tbl, 1 ex

Up!